Literature DB >> 21398617

CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation.

Soizic Garaud1, Ahsen Morva, Sébastien Lemoine, Sophie Hillion, Anne Bordron, Jacques-Olivier Pers, Christian Berthou, Rizgar A Mageed, Yves Renaudineau, Pierre Youinou.   

Abstract

B lymphocytes from chronic lymphocytic leukemia (CLL) display some CD5 transcripts for CD5 containing the known exon 1 (E1A) and other CD5 transcripts containing the new exon 1 (E1B). These malignant B cells, as well as B cell lines transfected with cDNA for E1A-cd5 or with cDNA for E1B-cd5 produce IL-10, raising the possibility that CD5 participates in the secretion of IL-10. We identified transcription factors involved in this production in CD5(+) B lymphocytes from CLL patients and in E1A-cd5-transfected or E1B-cd5-transfected Jok cells. STAT3 is activated via phosphorylation of serine 727 but also NFAT2 through its translocation into the nucleus. Chromatin immunoprecipitation experiments confirmed the role of STAT3 and allowed the discovery of a role for NFAT2 in IL-10 production. Both transcription factors bind not only to the enhancer of the Il-10 gene but also to the promoter of the Il-5 and Il-13 genes. Furthermore, transfection of B cell lines with E1A-cd5 or E1B-cd5 established that activation of STAT3 and NFAT2 is regulated by CD5. The same holds true for the production of IL-10, IL-5, and IL-13 and the expression of the receptors for these cytokines. This interpretation was confirmed by two experiments. In the first, downregulation of CD5 by small interfering RNAs lowered the production of IL-10. In the second experiment, transfection of the GFP-NFAT2 gene into B lymphocytes induced nuclear translocation of NFAT2 in CD5(+) but not in CD5(-) B cells. Thus, CD5 expression is associated with NFAT2 activity (and mildly STAT3 activity), indicating that CD5 controls IL-10 secretion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21398617     DOI: 10.4049/jimmunol.1003050

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Pulsed high-dose dexamethasone improves interleukin 10 secretion by CD5+ B cells in patients with primary immune thrombocytopenia.

Authors:  Fanli Hua; Lili Ji; Yanxia Zhan; Feng Li; Shanhua Zou; Xiaoyun Wang; Dongli Song; Zhihui Min; Song Gao; Yangjiong Wu; Hao Chen; Yunfeng Cheng
Journal:  J Clin Immunol       Date:  2012-06-06       Impact factor: 8.317

Review 2.  Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus.

Authors:  Aurélie De Groof; Patrice Hémon; Olivier Mignen; Jacques-Olivier Pers; Edward K Wakeland; Yves Renaudineau; Bernard R Lauwerys
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

3.  CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes.

Authors:  Soizic Garaud; Taher E Taher; Marjolaine Debant; Miguel Burgos; Sarra Melayah; Christian Berthou; Kaushal Parikh; Jacques-Olivier Pers; Damien Luque-Paz; Gilles Chiocchia; Maikel Peppelenbosch; David A Isenberg; Pierre Youinou; Olivier Mignen; Yves Renaudineau; Rizgar A Mageed
Journal:  Cell Mol Immunol       Date:  2016-08-08       Impact factor: 11.530

4.  DNA methylation modulates HRES1/p28 expression in B cells from patients with Lupus.

Authors:  Tinhinane Fali; Christelle Le Dantec; Yosra Thabet; Sandrine Jousse; Catherine Hanrotel; Pierre Youinou; Wesley H Brooks; Andras Perl; Yves Renaudineau
Journal:  Autoimmunity       Date:  2013-10-14       Impact factor: 2.815

5.  IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.

Authors:  S Drennan; A D'Avola; Y Gao; C Weigel; E Chrysostomou; A J Steele; T Zenz; C Plass; P W Johnson; A P Williams; G Packham; F K Stevenson; C C Oakes; F Forconi
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

6.  Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Authors:  Donna O'Dell Bunch; JulieAnne G McGregor; Nirmal B Khandoobhai; Lydia T Aybar; Madelyn E Burkart; Yichun Hu; Susan L Hogan; Caroline J Poulton; Elisabeth A Berg; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 8.237

7.  Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies.

Authors:  L T Aybar; J G McGregor; S L Hogan; Y Hu; C E Mendoza; E J Brant; C J Poulton; C D Henderson; R J Falk; D O Bunch
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

Review 8.  Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia.

Authors:  Audrey Mohr; Yves Renaudineau; Cristina Bagacean; Jacques-Olivier Pers; Christophe Jamin; Anne Bordron
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

Review 9.  Immunological aspects in chronic lymphocytic leukemia (CLL) development.

Authors:  Ricardo García-Muñoz; Verónica Roldan Galiacho; Luis Llorente
Journal:  Ann Hematol       Date:  2012-04-12       Impact factor: 3.673

10.  Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations.

Authors:  Domenico Maisano; Enrico Iaccino; Alessandro D'Ambrosio; Federico Chiurazzi; Vincenzo Dattilo; Mariangela Scalise; Massimo Gentile; Eleonora Vecchio; Nancy Nisticò; Annamaria Aloisio; Erika De Sensi; Giuseppe Fiume; Ileana Quinto; Selena Mimmi
Journal:  Front Oncol       Date:  2021-06-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.